Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01002248 · ClinicalTrials.gov registry record · Phase 3
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
A Phase 3 study, sponsored by AEterna Zentaris.
- Terminated
- Registry status
- Phase 3
- Development phase
- 135
- Enrollment target
NCT01002248: Clinical Trial Phase 3 study, sponsored by AEterna Zentaris.
NCT01002248 is a Phase 3 study that was terminated before completion, run by AEterna Zentaris. The registered enrollment target is 135 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01002248, a Phase 3 study, was terminated before completion, sponsored by AEterna Zentaris.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 135 participants
- Enrollment target
Study Summary
This is a randomized Phase III study to evaluate the efficacy and safety of perifosine when added to the combination of bortezomib and dexamethasone in multiple myeloma patients who have relapsed on a prior bortezomib treatment regimen.
Primary Outcome
Progression-free survival will be defined as the time between randomization and the date of progression that occurred during the Core Phase.
Interventions
- DRUG Dexamethasone
- DRUG Bortezomib
- DRUG Perifosine
- DRUG Perifosine Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2009-12 |
| Est. Completion | 2013-03 |
| Phase | Phase 3 |
Why NCT01002248 stopped before completion
NCT01002248 is an interventional study that assigns participants to a tested intervention. The registered 135 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 4 interventions - of which Dexamethasone is the first listed.
NCT01002248 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01002248 about?
NCT01002248 is a clinical study titled "Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients". This is a randomized Phase III study to evaluate the efficacy and safety of perifosine when added to the combination of bortezomib and dexamethasone in multiple myeloma patients who have relapsed on a prior bortezomib treatment regimen.
What is the current status of trial NCT01002248?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 135 participants. The study started on 2009-12. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01002248?
The interventions under investigation include: Dexamethasone (DRUG), Bortezomib (DRUG), Perifosine (DRUG), Perifosine Placebo (DRUG).
Who is sponsoring clinical trial NCT01002248?
This trial is sponsored by AEterna Zentaris, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01002248's enrollment target sits among peer trials
135 1582nd of 2000 higher than 416 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00870129 · 135 participants · NA
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
- NCT03666000 · 135 participants · Phase 1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04891510 · 135 participants · NA
A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
- NCT05121051 · 135 participants · Phase 2
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia